![David Martin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Martin
Fondatore presso
AvidBiotics Corp.
Profilo
David W.
Martin is the founder of AvidBiotics Corp., founded in 2005, where the title held is Chief Executive Officer & Director.
Dr. Martin was the founder of EOS Biotechnology, Inc., founded in 1997, where the title held was President & Chief Executive Officer in 2003.
Dr. Martin is also the founder of Pylum Biosciences, Inc.,Xyphos Biosciences, Inc...
Former jobs include President & Chief Executive Officer at Lynx Therapeutics, Inc. from 1995 to 1996; Chairman & Chief Executive Officer at GangaGen, Inc. in 2004; Director at Cubist Pharmaceuticals LLC from 1997 to 2009; Lead Director at Varian Medical Systems, Inc. from 2010 to 2012; Senior Vice President-Research & Development at Genentech, Inc. in 1990; Executive Vice President-Research & Development at DuPont Merck Pharmaceutical Co. in 1993; President at Chiron Therapeutics, Inc. in 1995; and Professor at Howard Hughes Medical Institute, Inc., The University of California, San Francisco, the University of California, Hastings, and Duke University School of Medicine.
Education includes a doctorate degree from Duke University.
Posizioni attive di David Martin
| Società | Posizione | Inizio |
|---|---|---|
AvidBiotics Corp.
 AvidBiotics Corp. Pharmaceuticals: MajorHealth Technology Develops non-antibody proteins as targeted therapeutics against bacteria, viral infections and cancer | Fondatore | 01/01/2005 |
Pylum Biosciences, Inc.
 Pylum Biosciences, Inc. BiotechnologyHealth Technology Develops avidocin platform technology capable of generating bactericidal protein complexes | Fondatore | - |
Xyphos Biosciences, Inc.
 Xyphos Biosciences, Inc. BiotechnologyHealth Technology Engages in biotechnology business | Fondatore | - |
Precedenti posizioni note di David Martin
| Società | Posizione | Fine |
|---|---|---|
| CUBIST PHARMACEUTICALS INC | Direttore/Membro del Consiglio | 04/06/2009 |
GangaGen, Inc.
 GangaGen, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel antibacterial proteins targeting infectious diseases | Amministratore Delegato | 01/01/2004 |
EOS Biotechnology, Inc.
 EOS Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic and diagnostic drugs | Amministratore Delegato | 01/04/2003 |
Lynx Therapeutics, Inc.
 Lynx Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops genetic analysis products for the pharmaceutical, biotechnology and agriculture industries | Presidente | 01/01/1996 |
Chiron Therapeutics, Inc. | Presidente | 01/01/1995 |
Formazione di David Martin
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
69
Relazioni di 1° grado
16
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 16 |
|---|---|
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Lynx Therapeutics, Inc.
Lynx Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Develops genetic analysis products for the pharmaceutical, biotechnology and agriculture industries | Health Technology |
Cubist Pharmaceuticals LLC
 Cubist Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Engages in research, development and commercialization of pharmaceutical products | Health Technology |
Varian Medical Systems, Inc.
 Varian Medical Systems, Inc. Medical SpecialtiesHealth Technology Designs, manufactures and supplies radiotherapy medical devices for treating cancer & develops related software solutions | Health Technology |
GangaGen, Inc.
GangaGen, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops novel antibacterial proteins targeting infectious diseases | Health Technology |
AvidBiotics Corp.
AvidBiotics Corp. Pharmaceuticals: MajorHealth Technology Develops non-antibody proteins as targeted therapeutics against bacteria, viral infections and cancer | Health Technology |
Duke University
 Duke University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Makes pharmaceuticals and drugs | Health Technology |
EOS Biotechnology, Inc.
EOS Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Develops therapeutic and diagnostic drugs | Health Technology |
Howard Hughes Medical Institute, Inc.
 Howard Hughes Medical Institute, Inc. Investment Trusts/Mutual FundsMiscellaneous Functions as a foundation or endowment | Miscellaneous |
The University of California, San Francisco
 The University of California, San Francisco Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Hastings
 University of California, Hastings Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Chiron Therapeutics, Inc. | |
Duke University School of Medicine
 Duke University School of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pylum Biosciences, Inc.
Pylum Biosciences, Inc. BiotechnologyHealth Technology Develops avidocin platform technology capable of generating bactericidal protein complexes | Health Technology |
Xyphos Biosciences, Inc.
Xyphos Biosciences, Inc. BiotechnologyHealth Technology Engages in biotechnology business | Health Technology |
